Lundbeck's New Partnering Focus: Link Up With Genmab On Research And Merck On Marketing Sycrest
This article was originally published in The Pink Sheet Daily
Executive Summary
Lundbeck to collaborate on CNS research with fellow Danish firm Genmab, and to exclusively market Merck's antipsychotic Sycrest outside the U.S., China and Japan.
You may also be interested in...
Deals Of The Week: Sanofi/TargeGen, Arena/Eisai, GSK/Genmab ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Lundbeck Defends Its Escitalopram Patent In Denmark, But Not In Spain
Lundbeck's top-selling product, Cipralex, is responsible for more than half its sales, but faces generic competition in Spain.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.